Jason Harris

Patients with PD-L1-positive non-small cell lung cancer that has metastasized to the brain did better with cemiplimab plus chemotherapy than with investigator's choice of chemotherapy.

Phase 1 data signals promise for botensilimab plus bastilimab for advanced ovarian cancer.

The phase 3 GRAPHITE study showed that vedolizumab plus standard prophylaxis after unrelated allogeneic hematopoietic stem cell transplantation was more effective vs placebo for the prevention of lower gastrointestinal graft-vs-host disease.

A 90-day complete response rate of 92% was observed with bispecific CAR T-cell therapy for patients with relapsed/refractory mantle cell lymphoma.

Anti-drug antibodies did not seem to affect how well the STRIDE regimen of durvalumab and tremelimumab or durvalumab alone worked in patients with unresectable hepatocellular carcinoma.

Nivolumab with chemotherapy or ipilimumab continued to have a clinically meaningful survival benefit vs with chemotherapy alone in patients with treatment-naïve advanced esophageal squamous cell carcinoma.

VITAL study results reveal survival advantage of birtamimab for patients with Mayo Stage IV amyloid light chain amyloidosis.

According to Ruth O'Regan, MD, BCI is the first genomic assay to demonstrate benefit from ovarian suppression.

Subsequent therapy rates were lower in patients with advanced renal cell carcinoma treated with the combination of lenvatinib and pembrolizumab vs those who received sunitinib in the CLEAR trial.

The combination of belzutifan and cabozantanib maintained antitumor activity in patients with advanced clear cell renal cell carcinoma who previously received immunotherapy.

Chemotherapy added to 1500 mg of MEDI5752, a PD-1/CTLA-4 bispecific monoclonal antibody, led to a doubling in duration of response compared with pembrolizumab and chemotherapy in patients with treatment-naïve nonsquamous non–small cell lung cancer.

The antibody-drug conjugate sacituzumab govitecan demonstrated superior overall response rate and progression-free survival in patients with breast cancer with limited options due to lack of high HER2 expression.

Rhenium-186 nanoliposome at doses exceeding 100 Gy showed promising results in patients with recurrent glioma, according to phase 1 findings from the ReSPECT-GBM trial presented at ESMO 2022.

An association between biallelic deletion of TNFRSF17 and resistance to therapies like chimeric antigen receptor T cells and T-cell engagers has been identified in myeloma.

An easy way to double survival for patients with lung cancer is by removing the barriers to screening.

The combination of temozolomide and nivolumab demonstrated promising overall response rates in patients who previously received chemotherapy for extensive-stage small cell lung cancer.

Ociperlimab plus tislelizumab revealed promising efficacy in adults with treatment-naïve, metastatic, PD-L1–positive non­–small cell lung cancer.

According to Ian E. Krop, MD, PhD, patritumab deruxtecan is responsible for producing clinically meaningful and durable antitumor activity in patients with HER3-expressing metastatic breast cancer, warranting further research.

After identifying a survival disparity among non-White Hispanic patients with pediatric neuroblastoma, investigators will next examine the interaction of survival and race, ethnicity, and poverty, acknowledging the intersectionality of these factors due to structural racism in the United States.

Findings from an analysis of the KarMMa study in patients with multiple myeloma signal that certain baseline characteristics are predictive of response to chimeric antigen receptor T-cell therapy.

In a phase 2 trial, rates of steroid-refractory chronic graft versus host disease and prednisone use following treatment with abatacept after stem cell transplant were reduced.

Results from a post-hoc exploratory analysis of the TALAPRO-1 study signal that high genomic loss of heterozygosity may be assiciated with enhanced response to talazoparib in patients with metastatic castration-resistant prostate cancer.

The bispecific antibody therapy AMF13 combined with preactivated and expanded natural killer cells showed encouraging activity in patients with heavily pretreated lymphoma.

Evidence for on-target activity of temferon has been demonstrated in patients with glioblastoma, according to the phase 1/2a TEM-GBM study.

Progress in the treatment of early-stage triple-negative breast cancer includes the now common use of neoadjuvant combinations of immunotherapy with chemotherapy.

A look back at apalutamide treatment in the the TITAN and SPARTAN trials showed that deep prostate-specific antigen responses lead to improvement in certain health-related quality of life factors.

In the CheckMate 649 trial, durable survival benefit was achieved with Nivolumab plus chemotherapy in patients with gastric or gastroesophageal junction cancer.

Based on updated findings from the phase 2 SUMMIT trial, a neratinib triplet and neratinib doublet can induce responses in patients with HER2-positive breast cancer.

Circulating tumor DNA should be used early and often by physcians who treat patients with early-stage triple-negative breast cancer.

Findings from the phase 2 REGOBONE study revealed that regorafenib did not confer progression-free survival benefit in patients with advanced or metastatic chordoma.